Navigation Links
UCLA stem cell researchers move toward treatment for rare genetic nerve disease
Date:5/10/2013

Led by Dr. Peiyee Lee and Dr. Richard Gatti, researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have used induced pluripotent stem (iPS) cells to advance disease-in-a-dish modeling of a rare genetic disorder, ataxia telangiectasia (A-T).

Their discovery shows the positive effects of drugs that may lead to effective new treatments for the neurodegenerative disease. iPS cells are made from patients' skin cells, rather than from embryos, and they can become any type of cells, including brain cells, in the laboratory. The study appears online ahead of print in the journal Nature Communications.

People with A-T begin life with neurological deficits that become devastating through progressive loss of function in a part of the brain called the cerebellum, which leads to severe difficulty with movement and coordination. A-T patients also suffer frequent infections due to their weakened immune systems and have an increased risk for cancer. The disease is caused by lost function in a gene, ATM, that normally repairs damaged DNA in the cells and preserves normal function.

Developing a human neural cell model to understand A-T's neurodegenerative process and create a platform for testing new treatments was critical because the disease presents differently in humans and laboratory animals. Scientists commonly use mouse models to study A-T, but mice with the disease do not experience the more debilitating effects that humans do. In mice with A-T, the cerebellum appears normal and they do not exhibit the obvious degeneration seen in the human brain.

Lee and colleagues used iPS cellderived neural cells developed from skin cells of A-T patients with a specific type of genetic mutation to create a disease-in-a-dish model. In the laboratory, researchers were able to model the characteristics of A-T, such as the cell's lack of ATM protein and its inability to repair DNA damage. The model also allowed the researchers to identify potential new therapeutic drugs, called small molecule read-through (SMRT) compounds, that increase ATM protein activity and improve the model cells' ability to repair damaged DNA.

"A-T patients with no ATM activity have severe disease but patients with some ATM activity do much better," Lee said. "This makes our discovery promising, because even a small increase in the ATM activity induced by the SMRT drug can potentially translate to positive effects for patients, slowing disease progression and hopefully improving their quality of life."

These studies suggest that SMRT compounds may have positive effects on all other cell types in the body, potentially improving A-T patients' immune function and decreasing their susceptibility to cancer.

Additionally, the patient-specific iPS cellderived neural cells in this study combined with the SMRT compounds can be an invaluable tool for understanding the development and progression of A-T. This iPS cellneural cell A-T disease model also can be a platform to identify more potent SMRT drugs. The SMRT drugs identified using this model can potentially be applied to most other genetic diseases with the same type of mutations.


'/>"/>

Contact: Shaun Mason
smason@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related medicine news :

1. Researchers Pinpoint Cause of Port-Wine Stain Birthmarks
2. Duke researchers describe how breast cancer cells acquire drug resistance
3. CWRU School of Medicine researchers discover new target for personalized cancer therapy
4. U of M researchers discover link between heart, blood, and skeletal muscle
5. Researchers determine where best to place defibrillators
6. Researchers plot locations where AEDs could save more lives
7. Gene Mutation Linked to Migraines, Researchers Say
8. Discovery of New Cause of Congenital Hydrocephalus Opens the Door to Collaborative Research Study, Hydrocephalus Association Commends Researchers
9. Northwestern Medicine researchers work to improve heart attack response time
10. NYU and NYU Langone researchers devise method for enhancing CEST MRI
11. Medicaid-insured children have limited access to dermatologists, SLU researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... A new digital ... are called back for additional examinations without sacrificing cancer detection, according to a ... the U.S. Food and Drug Administration approved digital breast tomosynthesis (DBT) for use ...
(Date:2/20/2017)... VA (PRWEB) , ... February 20, 2017 , ... Silverado ... Cambridge Healthcare to open and operate a state-of-the-art memory care community in Alexandria, Virginia. ... 2018 on a site just outside of Old Town. , The three-story community ...
(Date:2/20/2017)... ... February 20, 2017 , ... Clearwave is the ... on the Posiflex XT-series of touch screen terminals. Both companies will be showcasing ... Florida. The terminal provider Posiflex is helping to bridge the gap between healthcare ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... as an employee health benefit for companies that want to help members of ... providers, employees will have access to Watson’s suite of oncology offerings for insights ...
(Date:2/20/2017)... ... February 20, 2017 , ... Chuck E. Cheese’s® and ... Sundays, a joint event at Chuck E. Cheese’s locations throughout New England, New York ... needs, the opportunity to experience the fun of visiting Chuck E. Cheese’s in a ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... Feb. 21, 2017 Research and Markets has announced ... 2016" report to their offering. ... The latest research Rosacea Drugs Price Analysis and Strategies - ... The research answers the following questions: ... How are they positioned in the Global Rosacea market? ...
(Date:2/20/2017)... Taiwan , Feb. 21, 2017 Taiwan ... leading provider of non-invasive vital signs sensing solutions, today ... industry,s first finger-free wrist pulse oximeter, the oCare TM ... the wearable healthcare and medical devices space.  ... 100, provides a non-invasive, simple and reliable method to ...
(Date:2/20/2017)...  This Report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing ... Forms, and Liquid & Semi-solid Dosage Forms. The report provides separate ... Japan , Europe , ... the full report: http://www.reportlinker.com/p04707109-summary/view-report.html ... Annual estimates and forecasts are provided for ...
Breaking Medicine Technology: